InvestorsHub Logo

eicoman

10/22/16 10:36 AM

#26297 RE: mean gene #26292

I wish i had known the 2 aspects of the de-listing rule, that an extension can be granted for only one aspect of it,

therefore this r/s was obvious, they ran out of time on the PPS over $1, they had to do it, and now they can apply for an extension on the second part, market cap, due Nov 29,

the news to have possibly prevented the r/s isn't quite ready yet, i think the goal now should be to get the price over $5

On June 2, 2016, Apricus Biosciences, Inc. (the "Company") received a notice from the NASDAQ Listing Qualifications Staff that the Company no longer satisfies the minimum $35 million market value of listed securities requirement as required for continued listing on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(b)(2).

The Company intends to monitor the market value of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with NASDAQ's minimum market value rule by November 29, 2016